港股持续拉升。 1月2日，港股恒生科技指数午后持续走强，截至收盘涨4%，恒生指数涨2.76%，电力设备、国内零售、游戏软件、半导体、军工股等涨幅居前。 华虹半导体涨超9%，中芯国际涨超5%；科网股上涨，百度集团涨超9%，网易涨超6%，阿里巴巴、腾讯控股涨超4%。 创新药概念股走高，晶泰控股涨超6%，恒瑞医药涨超5%，四环医药涨超4%，信达生物、药明生物涨超3%，百济神州涨超2%。 光伏太阳能板块上涨，协鑫新能源涨超22%，协鑫科技、福莱特玻璃涨超3%。 （文章来源：证券时报） 富时中国A50指数期货日内涨超1%。 2025年A股市场大涨，展望2026年，在企业盈利改善、科技创新突破不断，以及估值吸引力推动下，多家机构认为中国资产具备持续反弹基础。 日前，招商基金首席投资官朱红裕认为，A股市场经过一轮周期性上涨，仍有部分板块与风格较为低估，中国资产2026年具备全球配置吸引力，并重点关 注四大主线机遇——具备全球竞争力的制造业龙头、未来供需格局趋于改善的行业龙头、估值处于底部且基本面可能有较高变化的行业、长期盈利回报较 高且估值不匹配的行业龙头。 高盛在最新报告中预测，到2027年底中国股市仍有38%的上涨空间 ...

Core Viewpoint - The Hong Kong stock market is experiencing a significant rally, with various sectors showing strong performance, indicating a positive outlook for the market in the near future [1][2]. Group 1: Market Performance - The Hang Seng Technology Index rose by 4% and the Hang Seng Index increased by 2.76%, with notable gains in sectors such as electric equipment, domestic retail, gaming software, semiconductors, and military industry [2]. - Semiconductor stocks saw substantial increases, with Hua Hong Semiconductor up over 9% and SMIC up over 5% [4]. - Internet companies also performed well, with Baidu Group rising over 9%, NetEase up over 6%, and Alibaba and Tencent both increasing by over 4% [4]. Group 2: Sector Highlights - Innovative drug concept stocks experienced gains, with Jingtai Holdings up over 6%, Hengrui Medicine up over 5%, and other pharmaceutical companies also showing positive movement [5]. - The photovoltaic solar panel sector saw significant growth, with GCL-Poly Energy rising over 22% and GCL-Technology and Fuyao Glass both increasing by over 3% [6]. Group 3: Future Market Outlook - The FTSE China A50 Index futures rose by over 1%, with expectations for a strong A-share market in 2025 and 2026 due to improving corporate earnings and attractive valuations [7]. - Multiple institutions believe that Chinese assets will have a sustained rebound basis, focusing on four main opportunities: globally competitive manufacturing leaders, industry leaders with improving supply-demand dynamics, undervalued sectors with potential for significant fundamental changes, and industry leaders with high long-term returns and mismatched valuations [7]. - Goldman Sachs predicts a 38% upside for the Chinese stock market by the end of 2027, citing improved core risks compared to previous years and a renewed interest from global investors [7]. - JPMorgan's chief strategist forecasts an 18% increase for the MSCI China Index and a 12% increase for the CSI 300 Index by the end of 2026, driven by capital flows and a recovery in real estate market sentiment [8].

1月2日，港股全线大涨，截至收盘，恒生指数涨逾2.7%，恒生科技指数涨4%，此外，韩国、新加坡、菲律宾等亚太股市均集体拉涨。 1月2日午后，港股市场手游股集体大涨，其中，腾讯控股盘中一度涨超4%，蓝港互动一度涨超10%，中手游盘中涨超9%、贪玩、网易、飞鱼科技、哔哩 哔哩、指尖跃动、第七大道跟涨。 华泰证券指出，根据游戏工委数据，2025年国内游戏市场实际销售收入预计达3507.89亿元，同比增长7.68%；用户规模突破6.83亿，同比增长1.35%，游 戏市场规模增长主要受益于用户ARPU（每用户平均收入）提升。对于游戏板块，建议关注三条主线：长线运营+出海SLG/策略龙头；新品周期+费用率预 期拐点的标的；商业模式从产品向平台转向的公司。同时关注AI赋能游戏玩法创新。 据媒体报道，业内人士普遍看好今年创新药行业发展，在产业政策对真创新、高水平创新的支持下，大量创新药BD（商务拓展）将密集落地。商保实施 与集采优化双轮推动下，创新药产业链高景气度有望延续，高价值创新药有望迎来第二增长曲线。 贵金属方面，现货黄金突破4380美元/盎司，涨超1.4%。现货白银日内一度涨超3.5%，突破74美元/盎司。 1月2日 ...

1月2日，港股全线大涨，截至收盘，恒生指数涨逾2.7%，恒生科技指数涨4%，此外，韩国、新加坡、 菲律宾等亚太股市均集体拉涨。 1月2日午后，港股市场手游股集体大涨，其中，腾讯控股盘中一度涨超4%，蓝港互动一度涨超10%， 中手游盘中涨超9%、贪玩、网易、飞鱼科技、哔哩哔哩、指尖跃动、第七大道跟涨。 华泰证券指出，根据游戏工委数据，2025年国内游戏市场实际销售收入预计达3507.89亿元，同比增长 7.68%；用户规模突破6.83亿，同比增长1.35%，游戏市场规模增长主要受益于用户ARPU（每用户平均 收入）提升。对于游戏板块，建议关注三条主线：长线运营+出海SLG/策略龙头；新品周期+费用率预 期拐点的标的；商业模式从产品向平台转向的公司。同时关注AI赋能游戏玩法创新。 1月2日，港股创新药概念股持续走高，晶泰控股一度涨超8%，恒瑞医药涨超5%，四环医药涨超4%，信 达生物、药明生物、百济神州跟涨。 据媒体报道，业内人士普遍看好今年创新药行业发展，在产业政策对真创新、高水平创新的支持下，大 量创新药BD（商务拓展）将密集落地。商保实施与集采优化双轮推动下，创新药产业链高景气度有望 延续，高价值创新药有望 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 四環醫藥控股集團有限公司 呈交日期: 2026年1月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00460 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 100,000,000,000 | HKD | | 0.01 | HKD | | 1,000,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 100,000,000,000 | HKD | | 0.01 | HKD | | 1,000,000 ...

Group 1 - The core viewpoint of the news is that Hong Kong's innovative drug concept stocks experienced a collective rise, indicating positive market sentiment in the pharmaceutical sector [1] Group 2 - Jingtai Holdings (02228) saw an increase of 6.13%, with a latest price of 10.040 and a total market capitalization of 43.206 billion [2] - Hengrui Medicine (01276) rose by 4.63%, with a latest price of 74.550 and a total market capitalization of 494.803 billion [2] - SiHuan Pharmaceutical (00460) increased by 4.07%, with a latest price of 1.280 and a total market capitalization of 11.707 billion [2] - Innovent Biologics (01801) experienced a rise of 3.34%, with a latest price of 78.800 and a total market capitalization of 135.599 billion [2] - WuXi Biologics (02269) increased by 3.18%, with a latest price of 32.440 and a total market capitalization of 133.916 billion [2] - China National Pharmaceutical Group (01177) rose by 3.07%, with a latest price of 6.370 and a total market capitalization of 119.506 billion [2] - BeiGene (06160) saw an increase of 2.68%, with a latest price of 184.100 and a total market capitalization of 283.639 billion [2] - Kingstar Bio (01548) rose by 2.66%, with a latest price of 12.750 and a total market capitalization of 27.874 billion [2] - Genscript Biotech (01952) increased by 2.49%, with a latest price of 37.900 and a total market capitalization of 13.4 billion [2] - WuXi AppTec (02359) saw a rise of 2.13%, with a latest price of 100.800 and a total market capitalization of 300.763 billion [2]

Group 1 - The core viewpoint of the article highlights the significant rise in Hong Kong's innovative drug concept stocks, indicating a positive trend in the sector [2] - Jingtai Holdings experienced a surge of over 6%, reflecting strong investor interest and confidence in the company [2] - Hengrui Medicine saw an increase of over 5%, suggesting robust performance and market positioning [2] - Four Seasons Pharmaceutical rose by more than 4%, indicating a favorable market response [2] - Innovent Biologics and WuXi Biologics both increased by over 3%, showcasing the overall strength of the innovative drug sector [2] - BeiGene's stock rose by over 2%, further contributing to the positive sentiment in the market [2]

Summary of Key Points Core Viewpoint - On December 29, 55 Hong Kong-listed companies conducted share buybacks, totaling 37.9 million shares and an aggregate amount of HKD 999 million [1][2]. Group 1: Major Companies Involved in Buybacks - Tencent Holdings repurchased 1.057 million shares for HKD 636 million, with a yearly total buyback amount of HKD 78.765 billion [1][2]. - Xiaomi Group-W bought back 3.9 million shares for HKD 151 million, with a total buyback amount of HKD 6.136 billion for the year [1][2]. - China COSCO Shipping Holdings repurchased 3.46 million shares for HKD 47.9 million, with a total buyback amount of HKD 6.866 billion for the year [1][2]. Group 2: Buyback Statistics - The highest buyback amount on December 29 was from Tencent Holdings at HKD 636 million, followed by Xiaomi Group-W at HKD 151 million [1][2]. - The largest number of shares repurchased on December 29 was by Four Seasons Medicine, with 8 million shares, followed by Xiaomi Group-W and China COSCO Shipping Holdings with 3.9 million and 3.46 million shares, respectively [1][2]. Group 3: Additional Companies and Their Buyback Data - Kingsoft repurchased 713,600 shares for HKD 20 million, with a total buyback amount of HKD 33.465 million for the year [2]. - Kuaishou-W bought back 310,000 shares for HKD 20 million, with a total buyback amount of HKD 306.840 million for the year [2]. - Other notable companies include Miniso Group, which repurchased 320,600 shares for HKD 1.195 million, and Four Seasons Medicine, which had a total buyback amount of HKD 15.332 million for the year [2][3].

Group 1 - The article highlights the stock buybacks conducted by various companies on December 29, 2025, with Tencent Holdings (00700) leading in both the number of shares repurchased and the total amount spent [1][2] - Tencent Holdings repurchased 1.057 million shares for a total of 636 million, representing 1.087% of its total share capital [2] - Other notable companies involved in buybacks include Xiaomi Group-W (01810) with 3.9 million shares repurchased for 151 million, and China Merchants Industry Holdings (01919) with 3.46 million shares for 47.9 million [2] Group 2 - The total number of shares repurchased by various companies in 2025 includes 9.987 million for Tencent, 1.42 million for Xiaomi, and 1.19 million for China Merchants Industry [2] - The buyback amounts for other companies vary, with notable figures such as Kuaishou-W (01024) repurchasing 310,000 shares for 19.97 million and Sihuan Pharmaceutical (00460) repurchasing 8 million shares for 10.01 million [2] - The data indicates a trend of companies engaging in share buybacks as a strategy to enhance shareholder value [1][2]

四环医药(00460)发布公告，于2025年12月29日斥资1000.88万港元回购800万股。 ...